Table 2.
Correlation between PD-L1 and PD-1 expression and clinicopathologic parameters in thymic carcinoma.
| Parameters | PD-L1 (N = 60) | PD-1 (N = 60) | ||||
|---|---|---|---|---|---|---|
| High (n = 21, %) | Low (n = 39, %) | P-value | High (n = 33, %) | Low (n = 27, %) | P-value | |
| Age† | 56.0 ± 9.41 | 55.69 ± 12.10 | 0.433 | 58.0 ± 11.80 | 53.11 ± 985 | 0.091 |
| Gender | 0.573 | 0.183 | ||||
| Male | 15 (71.4%) | 24 (61.5%) | 19 (57.6%) | 20 (74.1%) | ||
| Female | 6 (28.6%) | 15 (38.5%) | 14 (42.4%) | 7 (25.9%) | ||
| Masaoka stage | 0.835 | 0.644 | ||||
| I | 5 (23.8%) | 10 (25.6%) | 10 (30.3%) | 5 (18.5%) | ||
| IIa | 2 (9.5) | 7 (17.9%) | 6 (18.2%) | 3 (11.1%) | ||
| IIb | 1 (4.8%) | 2 (5.1%) | 1 (3.0%) | 2 (7.4%) | ||
| III | 7 (33.3%) | 13 (33.3%) | 9 (27.3%) | 11 (40.7%) | ||
| IVa | 2 (9.5%) | 1 (2.6%) | 1 (3.0%) | 2 (7.4%) | ||
| IVb | 4 (19.0%) | 6 (15.4%) | 6 (18.2%) | 4 (14.8%) | ||
| Size | 0.218 | 0.554 | ||||
| <5 cm | 3 (14.3%) | 12 (30.8%) | 7 (21.2%) | 8 (29.6%) | ||
| ≥5 cm | 18 (85.7%) | 27 (69.2%) | 26 (78.8%) | 19 (70.4%) | ||
| Capsule formation | 0.404 | 0.903 | ||||
| Present | 1 (4.8%) | 6 (15.4%) | 4 (14.1%) | 3 (11.2%) | ||
| Absent | 10 (95.2%) | 33 (84.6%) | 29 (87.9%) | 24 (88.9%) | ||
| Capsule invasion | 0.866 | 0.599 | ||||
| Present | 13 (61.9%) | 25 (64.1%) | 22 (66.7%) | 16 (59.3%) | ||
| Absent | 8 (38.1%) | 14 (35.9%) | 11 (33.3%) | 11 (40.7%) | ||
| LN metastasis | 0.606 | 0.620 | ||||
| Present | 2 (9.5%) | 2 (5.1%) | 3 (9.1%) | 1 (3.7%) | ||
| Absent | 19 (90.5%) | 37 (94.9%) | 30 (90.9%) | 26 (94.9%) | ||
| Distant metastasis | 0.622 | 0.521 | ||||
| Present | 5 (23.8%) | 7 (18.4%) | 8 (24.2%) | 4 (15.4%) | ||
| Absent | 16 (76.2%) | 31 (81.6%) | 25 (75.8%) | 22 (84.6%) | ||
| Myasthenia gravis | None | None | ||||
| Present | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Absent | 21 (100%) | 39 (100%) | 33 (100%) | 27 (100%) | ||
| Neoadjuvant Tx | 0.149 | 0.262 | ||||
| No | 11 (6.7%) | 30 (76.9%) | 24 (72.7%) | 17 (63.0%) | ||
| CTx | 9 (42.9%) | 8 (20.5%) | 9 (27.3%) | 8 (29.6%) | ||
| RTx | 1 (4.8%) | 1 (2.6%) | 0 (0%) | 2 (7.4%) | ||
| Adjuvant Tx | 0.934 | 0.578 | ||||
| No | 6 (28.6%) | 11 (28.2%) | 10 (30.3%) | 7 (25.9%) | ||
| CTx | 3 (14.3%) | 7 (17.9%) | 4 (12.1%) | 6 (22.2%) | ||
| RTx | 12 (57.1%) | 21 (53.8%) | 19 (57.6%) | 14 (51.9%) | ||
| PD-1 | 0.277 | |||||
| High | 14 (42.4%) | 7 (25.9%) | ||||
| Low | 19 (57.6%) | 20 (74.1%) | ||||
†
Analyzed using a t-test.
Tx, treatment; CTx, chemotherapy; RTx, radiation therapy.